Percentage of surgical pathology reports for primary colorectal, endometrial, gastroesophageal or small bowel carcinoma, biopsy or resection, that contain impression or conclusion of or recommendation for testing of mismatch repair (MMR) by immunohistochemistry (biomarkers MLH1, MSH2, MSH6, and PMS2), or microsatellite instability (MSI) by DNA-based testing status, or both
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.8 Level Of Analysis1.9 Care Setting1.20 Testing Data Sources
-
1.14 Numerator
Surgical pathology reports that contain impression or conclusion of or recommendation for testing of MMR by immunohistochemistry, MSI by DNA-based testing status, or both
-
1.15 Denominator
All surgical pathology reports for primary colorectal, endometrial, gastroesophageal or small bowel carcinoma, biopsy or resection
-
Exclusions
1) Patients with an existing diagnosis of Lynch Syndrome
2) Squamous cell carcinoma of the esophagus
-
Most Recent Endorsement ActivityEndorsed Primary Care and Chronic Illness Fall Cycle 2021Initial EndorsementLast Updated
-
StewardCollege of American PathologistsSteward Organization POC EmailSteward Organization Copyright
© College of American Pathologists. All rights reserved. The College of American Pathologists (CAP) owns all rights, title, and interests in this quality measure. This quality measure is provided solely for the benefit of CAP, its members and the Pathologists Quality Registry for the purposes specified herein and for other CAP purposes. It may not be used by other parties except with prior written approval of the CAP. Email [email protected] for more information.
-
-
-
Risk Adjustment
-
-
-
6.1.2 Current or Planned Use(s)6.1.3 Current Use(s)
-
Planned Use
-